BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChemDiv Research Institute Announces R&D Collaborations With Abbott Laboratories (ABT) in Russia


7/9/2012 9:13:40 AM

MOSCOW--(Marketwire - July 09, 2012) - ChemDiv Research Institute (CDRI) at the ChemRar Hi-Tech Centre and Abbott, a global healthcare company, announced at the St. Petersburg International Economic Forum that they have signed an agreement to launch several R&D projects in Russia. This initiative is aimed to broaden therapeutic opportunities for the patients in Russia and to contribute to building an innovative pharmaceutical industry in Russia.

The first collaboration between CDRI, the research entity of ChemRar Hi-Tech Centre, and Abbott will focus on creating an advanced new forms of the existing Abbott's pharmaceutical products to increase patient's compliance and decrease medicine intake. These goals will be accomplished by developing new technologies and by introducing new medicine formulations. In addition to the abovementioned, there are some other ongoing discussions between CDRI and Abbott regarding several programs for joint small molecule medicine's development and enhancement.

It was also announced that ChemRar's R&D company, Intellectual Dialog, launched a research project with Abbott aimed at prevention and treatment of selected viral diseases impacting children and the elderly. Intellectual Dialog will conduct discovery research in collaboration with Abbott.

"CDRI is actively involved in both developing new molecules and improving existing drugs, covering the full cycle from pre-clinical development through manufacturing. Our collaboration with global healthcare leader Abbott will draw on the company's expertise and technologies and Russia's significant scientific potential to effectively develop new products of the highest quality based on existing drugs," said Nikolay Savchuk, Chairman at CDRI.

This collaboration is aligned with the Russian Government initiative to modernize the Russian pharmaceutical industry as envisioned in the Development Strategy for the Pharmaceutical Industry through 2020.

About ChemDiv Research Institute:
ChemDiv Research Institute (CDRI) is a fully integrated discovery and development Contract Research Organization (CRO), subsidiary of ChemDiv, Inc of San Diego CA, established at ChemRar High Tech Center in Khimki Moscow with subsidiaries in Russia and Ukraine, business and logistics operations around the world. CDRI collaborates with pharmaceutical and biotech partners by enabling them to accelerate R&D programs to higher value inflection points. One of the industry's most established CRO, CDRI offers integrated Discovery outSource™ solutions that cover a complete range of disciplines needed to bring a new project in CNS, oncology, inflammation, metabolic, infectious and other diseases from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept, including Phases I-III and to market registration.


Media Contacts

ChemRar Russia
Elena Surina
Email Contact
+7 (926) 206-78-71

ChemRar US
Olga Dmitrieva
Email Contact
(858) 794-48-60



Read at BioSpace.com

Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES